Niklas Mattsson-Carlgren Profile
Niklas Mattsson-Carlgren

@NiklasMattsson4

Followers
417
Following
121
Media
12
Statuses
60

Research on Alzheimer's disease and other neurological diseases

Sweden
Joined August 2019
Don't wanna be here? Send us removal request.
@NiklasMattsson4
Niklas Mattsson-Carlgren
4 years
Check out this paper, a collaboration between Lund University and UCSF Memory and Aging Center, where we show that CSF biomarkers have very high accuracy for autopsy confirmed Alzheimer's disease https://t.co/mjMnr9nee5 @OskarHansson9 @RabLab_UCSF @MultiparkL @biofinder_study
0
2
6
@NiklasMattsson4
Niklas Mattsson-Carlgren
4 years
Enjoy this podcast episode about our recent Neurology paper on CSF biomarkers in autopsy confirmed neurodegenerative diseases! https://t.co/zvVsymC4Di @biofinder_study @OskarHansson9 @RabLab_UCSF
0
3
7
@MultiparkL
MultiPark at LundU
4 years
Does #Abeta38 affect the risk of #AD ? @alzforum discusses interesting findings by Nicholas Cullen, @NiklasMattsson4, @SebastianPalmqv and @OskarHansson9. #neuroscience #biomarkers #alzheimersdisease @Medfak_LU
@alzforum
Alzforum
4 years
People with early Alzheimer's are less likely to progress to dementia if they have a lot of Aβ38. Should γ-secretase modulators be revived? #Alzheimersdisease @lunduniversity
0
3
3
@UCSFmac
UCSF Fein Memory and Aging Center
4 years
Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and FTLD. Class II evidence. https://t.co/pxpYm1hfIo @NiklasMattsson4 @grinberg_t @RikOssenkoppele @ajehrenberg @SalvoSpinaSF @JulioCRojas10 @relajoie @leoiacca @OskarHansson9 @AlbaLanguage @RabLab_UCSF
0
4
8
@UCSFmac
UCSF Fein Memory and Aging Center
4 years
Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and FTLD. 101 patients w/ CSF & neuropath data. https://t.co/pxpYm1hfIo @NiklasMattsson4 @grinberg_t @RikOssenkoppele @ajehrenberg @SalvoSpinaSF @JulioCRojas10 @relajoie @leoiacca @OskarHansson9 @RabLab_UCSF
0
9
28
@MultiparkL
MultiPark at LundU
4 years
0
1
4
@MultiparkL
MultiPark at LundU
4 years
Findings from @biofinder_study reveal genetic influence on longitudinal #cognitivedecline in early stages of #AD, partially mediated by #Abeta pathology. @SciReports @SebastianPalmqv @OskarHansson9 @NiklasMattsson4 @Medfak_LU https://t.co/SRHZYVWfO5
0
4
12
@MultiparkL
MultiPark at LundU
4 years
80 % of the world’s #HighlyCitedResearchers at #lunduniversity comes from MultiPark. Congratulations to @OskarHansson9 @sara_linse and @NiklasMattsson4. And to @BrundinPatrik, previously initiating MultiPark. @Medfak_LU #Clarivate https://t.co/x6UU5o4nBn
1
4
7
@NiklasMattsson4
Niklas Mattsson-Carlgren
5 years
In this new paper https://t.co/cLMMI0Jn7W, we show how changes in levels of soluble phosphorylated tau depend on deposition of both beta-amyloid and tau aggregates in the brain in Alzheimer's disease @biofinder_study @EmboMolMed
@biofinder_study
BioFINDER
5 years
Our recent paper shows that plasma pTau is mainly related to amyloid plaques in early disease and tau tangles in later disease stages. That is, soluble pTau is associated with both pathologies and not simply a marker of any of these pathologies per se.
0
6
17
@biofinder_study
BioFINDER
5 years
Our recent paper shows that plasma pTau is mainly related to amyloid plaques in early disease and tau tangles in later disease stages. That is, soluble pTau is associated with both pathologies and not simply a marker of any of these pathologies per se.
0
16
34
@OskarHansson9
Oskar Hansson
5 years
Great collaboration evaluating plasma pTau in two cohorts characterized using either neuropathology (Banner) or PET (BioFINDER). Especially thanks to @NiklasMattsson4. @MultiparkL @lunduniversity
@biofinder_study
BioFINDER
5 years
Our recent paper shows that plasma pTau is mainly related to amyloid plaques in early disease and tau tangles in later disease stages. That is, soluble pTau is associated with both pathologies and not simply a marker of any of these pathologies per se.
0
2
14
@NicholasAshton
Nicholas Ashton
5 years
I am delighted to share our latest blood biomarker work published in @alzassociation. We investigated baseline & longitudinal #pTau, #NfL, #GFAP, #tTau, #Aβ to predict diagnosis & grey matter changes in individuals not predetermined by CSF/imaging. https://t.co/PJ2ldGKwTl 1/n
2
21
84
@NiklasMattsson4
Niklas Mattsson-Carlgren
5 years
In this proteomics study https://t.co/aYcEtHOwIE we found evidence of accelerated inflammatory ageing in Alzheimer's disease, supporting the view that inflammatory pathways are critically involved in Alzheimer's disease @biofinder_study @LuWcmm @OskarHansson9
0
1
13
@NiklasMattsson4
Niklas Mattsson-Carlgren
5 years
Very happy to present this work on Time Between Milestone Events in The Alzheimer's Disease Amyloid Cascade https://t.co/gcbCcuvhG1. One key finding was that changes in tau started quite early. Perhaps DMTs must be initiated prior to significant Aβ pathology? @biofinder_study
2
16
80
@NiklasMattsson4
Niklas Mattsson-Carlgren
5 years
Plasma phosphorylated tau (P-tau) correlate with imaging measures of brain atrophy over time in AD! Perhaps repeated blood tests can track atrophy, both in clinical practice and in drug trials, to find therapies that reduce degeneration? https://t.co/rHqyBtPylg. @biofinder_study
0
6
23
@NiklasMattsson4
Niklas Mattsson-Carlgren
5 years
In this paper, we demonstrate how plasma and CSF biomarkers can be used for individualized prognostication of cognitive decline due to Alzheimer's disease. We hope that this will improve patient management, help patients and families, and speed up drug trials for new therapies.
@NatureAging
Nature Aging
5 years
4y prognosis of cognitive decline and #dementia due to Alzheimer’s disease in patients with mild cognitive impairment based on a combination of tau and neurodegeneration https://t.co/QCNzzyxyZG #PlasmaBiomarkers @OskarHansson9, @NiklasMattsson4, @SebastianPalmqv, @biofinder_study
0
6
18
@NiklasMattsson4
Niklas Mattsson-Carlgren
5 years
Plasma P-tau depends on both beta-amyloid and tau pathology in Alzheimer's disease. Early in the disease, plasma P-tau may be increased in response to beta-amyloid pathology. In later disease stages, plasma P-tau is associated with tau aggregation in the neocortex.
@biofinder_study
BioFINDER
5 years
What AD pathologies are measured by plasma P-tau? In this preprint, using both neuropathology and PET, we show that plasma p-tau217 levels are predicted by both amyloid plaques and tau tangles.
0
11
20
@RikOssenkoppele
RikOssenkoppele
5 years
Excellent review about #APOE ε2: "Protective mechanism and therapeutic implications for #Alzheimer’s disease", https://t.co/79KYDIb4Nj. Can we develop therapies that mimic APOE ε2 effects to prevent/delay/cure AD?
1
6
32
@SJ_Schreiner
Simon J. Schreiner
5 years
New data from the @biofinder_study suggest that enlarged perivascular spaces, which previously have been implicated in AD+pathological #aging, are related to small vessel but not #Alzheimer disease or cognition: https://t.co/yxLbyCis3e @GreenJournal @OskarHansson9 @NiklasMattsson4
0
5
9
@d_schonhaut
Daniel Schonhaut
5 years
You could pay every American $3,000 on the money that the wealthiest 0.0002% have *increased* their wealth by during the pandemic -__-
@BernieSanders
Bernie Sanders
5 years
The real looting in America is 644 billionaires becoming $931 billion richer during a pandemic, while Republicans continue to deny 25 million+ unemployed Americans the $600/week they need to pay for rent & put food on the table. We need an economy that works for all, not the 1%.
0
2
6